4D Molecular Therapeutics Inc 4D-310 Phase 1/2 and 4D-110 Phase 1/2 Clinical Data Update Call Transcript
Hello, ladies and gentlemen. Thank you for standing by, and welcome to 4D Molecular Therapeutics 4D-310 and 4D-110 Clinical Data Conference Call. (Operator Instructions) As a reminder, today's call is being recorded. With that, I will hand over the call to Mike Zanoni, Vice President, Head of Investor Relations, who will make introductory comments.
Thank you, Van, and welcome, everyone, to 4D Molecular Therapeutics 4D-310 and 4D-110 Clinical Data Conference Call. Today's webcasted presentation as well as this afternoon's press release describing the initial results from our Phase I/II clinical study of 4D-310 in patients with Fabry disease as well as an update on the 4D-110 choroideremia Phase I/II clinical trial are accessible in the Investors section of the 4D Molecular Therapeutics website.
With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; Dr. Robert Fishman, our Chief Medical Officer; Dr. [Rafi] Schiffmann, our SVP and Clinical Therapeutic Area Head, Lysosomal Storage Diseases and Cardiology; and Augie Moretti,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |